摘要
目的:探讨胰腺癌组织XIAP蛋白的表达与临床病理特征和生存期的关系。方法:收集胰腺癌组织标本54例及正常胰腺组织14例,并随访其生存期;免疫组织化学检测XIAP的表达;标准评定采用半定量法。结果:54例胰腺癌组织中48例(88.9%)XIAP阳性表达,14例胰腺正常组织中XIAP阳性表达率为50.0%。XIAP表达与胰腺癌组织分化程度呈负相关(P<0.05),而与临床TNM分期无关。XIAP表达与肿瘤是否发生血管浸润和淋巴结转移有关,P<0.05。XIAP表达阴性及弱阳性与表达中等阳性及强阳性比较,术后生存率差异有统计学意义,P=0.041。多因素分析结果显示,TNM分期、XIAP蛋白表达水平为独立预后因子。结论:XIAP表达水平高的胰腺癌组织恶性程度更高,发生血管浸润及淋巴结转移的机会更高;XIAP表达水平与患者术后生存期有关;TNM分期、XIAP蛋白表达水平可作为评价预后的有价值指标。
OBJECTIVE:To explore the correlation of XIAP protein expression with the clinical pathological features and the survival of patients. METHODS: Totally 54 cases of pancreatic carcinoma tissues and 14 cases of normal pancreatic tissues were recruited in this study. All patients were followed up. Expression of XIAP was examined by immunohistochemistry in all pancreatic tissues. A semiquantitative scoring system was used to assess XIAP. RESULTS: XIAP protein was observed in 48 (88. 9 % ) specimens in pancreatic carcinoma tissues. The positivity rate of XIAP expression in normal pancreatic tissues was 50. 0%. The expression of XIAP was negatively related with the dif- ferentiation degree of pancreatic carcinoma(P〈0.05), but XIAP expression had no correlation with clinical staging. The XIAP expression had correlation with vessel invasion or lymph node metastasis (P〈0.05). The survival rate was significantly different between the patients with negative and weakly positive expression and those with moderately and strongly positive expression (P = 0.041). Multivariate analysis showed that TNM stage, XI- AP expression were independent prognosic factors. CONCLUSIONS: The high level of XIAP expression in pancreatic carcinoma suggests a high degree of malignant and a high rate of vessel invasion or lymph node metastasis. The expression degree of XIAP have correlation with the survival rate of patients with pancreatic carcinoma. TNM stage, XIAP expression can be used as an valuable index for predicting the prognosis.
出处
《中华肿瘤防治杂志》
CAS
2011年第19期1537-1540,共4页
Chinese Journal of Cancer Prevention and Treatment
关键词
胰腺肿瘤
抑制蛋白
免疫组织化学
预后
pancreatic neoplasms
arrestin
immunohistochemistry
prognosis